Organon Q4 revenue $1.60B (+8% YoY); FY23 EPS $3.99; FY24 guidance $6.2-6.5B

Organon & Co.

2023-FY EPS reported $3.99 revenue$6,263,000,000

FY23 revenue $6.3B (+1% as-reported, +3% constant currency).
FY23 diluted EPS $3.99, non-GAAP adjusted diluted EPS $4.14; Adj. EBITDA $1.9B (31% margin).
Q4 revenue $1.60B (+8% YoY); Q4 non-GAAP adj. diluted EPS $0.88 (+9%).
Biosimilars rev +49% (Hadlima >doubled); Women's Health +7% (Follistim +63% ex-FX).
FY2024 guidance: revenue $6.2-6.5B, Adj. EBITDA margin 31-33%.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Organon & Co. updated its the quarter and full year ended December 31, 2023 guidance (reaffirmed).

Period: the quarter and full year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 15, 2024, Organon & Co. (the “ Company ”) issued a press release (the “ Earnings Release ”) regarding its results for the quarter and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Organon & Co. filing history →

Source: SEC EDGAR

accession 0001104659-24-024358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.